Luminopia
Aspen, US · Founded 2015 · Delaware corporation · 9 known investors
Find your way into Luminopia
238 people in our graph share verified history with the Luminopia team — schools, employers, funds. One of them is your warm intro.
Anika Guptaunlockedknows Scott Xiao · together at Broad Institute (overlapped)
×8knows the team · via Broad Institute
knows the team · via Evelo Biosciences
knows the team · via Bluebird Bio
knows the team · via Wyss Institute for Biologically Inspired Engineering
Luminopia is an FDA-cleared binocular therapy for amblyopia in children aged 4-12 that uses a VR headset to stream the child's favorite TV shows as treatment, replacing traditional eye patches. Clinically tested in US trials, the therapy is prescribed by doctors and requires one hour of use per day, six days a week.
Founders & leadership
Luminopia was founded in 2015 by Scott Xiao and Dean Travers.
SX
Scott XiaoinCo-Founder & CEOScott Xiao is co-founder and CEO of Luminopia, which delivers FDA-cleared binocular therapy for amblyopia using a VR headset to present television content differently to each eye. He has background in the intersection of technology and healthcare.
DT
Dean TraversinCo-Founder
BR
Brion RaymondinCBO
DM
Drew MoweryinVP of Commercial StrategyHe brings over 20 years of experience in biopharmaceutical marketing, product planning, clinical development, and sales leadership across pipeline, launch, and established products.
HW
Hank WuinCOOHe previously held leadership roles in digital health and R&D at Biogen and Evelo Biosciences, with earlier experience in biotech analytics and medical AI, and holds degrees from UC Berkeley in electrical engineering and computer science, Johns Hopkins University in biotech, and MIT Sloan in business.
SA
Sunny AtwalinVP of Engineering
AW
ALEXANDER WENDLANDNamed on SEC filing
Investors · 9
ShangBay Capital LLC✓ verifiedPalo Alto
Bantam GroupWestwood
Good FriendsSan Francisco · $250K – $1Mvia Alexandra Cowie · inferred
NXT VenturesMarblehead · $250K – $1M
Sony Ventures CorporationTokyo
US Venture PartnersMenlo Park · $500K – $10Mvia Casey Tansey · board
U.S. Venture PartnersreportedMinneapolis
Also in the syndicate · 2
Broadfin AdvisorsVertical Group
Reported raises · per SEC filings
Form D private placements$36.5M disclosed across 7 rounds · 2016–2023
▶$15.8MraisedJun 2023 · 10 investors · BiotechnologyRule 506(b)
▶$15.8MraisedJun 2023 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott XiaoExecutive Officer, Director
- Casey TanseyDirector
- Robert LangerDirector
- Dean TraversDirector
- William DaiDirector
- Mark JacobsteinDirector
- Offering amount
- $16.8M
- Amount sold
- $15.8M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedOct 2022 · 15 investors · BiotechnologyRule 506(b)
▶$4.1MraisedOct 2022 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey DunnDirector
- Scott XiaoExecutive Officer, Director
- Dean TraversDirector
- Robert LangerDirector
- Mark JacobsteinDirector
- Michelle LeeDirector
- William DaiDirector
- Offering amount
- $5.1M
- Amount sold
- $4.1M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedDec 2019 · 29 investors · Other Health CareRule 506(b)
▶$11.1MraisedDec 2019 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Scott XiaoExecutive Officer
- Mark JacobsteinDirector
- Jeffrey DunnDirector
- Dean TraversExecutive Officer, Director, Promoter
- Joi ItoDirector
- Robert LangerDirector
- Offering amount
- $13.6M
- Amount sold
- $11.1M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.6MraisedSep 2017 · 8 investors · Other Health CareRule 506(b)
▶$3.6MraisedSep 2017 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- SCOTT XIAOExecutive Officer, Director
- ALEXANDER WENDLANDExecutive Officer, Director
- MARK DOCKSERExecutive Officer
- DEAN A. TRAVERSExecutive Officer, Director, Promoter
- Offering amount
- $5.1M
- Amount sold
- $3.6M
- Minimum investment
- $10K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.3MraisedSep 2017 · 3 investors · Other Health CareRule 506(b)
▶$1.3MraisedSep 2017 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- SCOTT XIAOExecutive Officer, Director
- MARK DOCKSERExecutive Officer
- DEAN A. TRAVERSExecutive Officer, Director, Promoter
- ALEXANDER WENDLANDExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$410KraisedDec 2016 · 8 investors · OtherRule 506(b)
▶$410KraisedDec 2016 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- SCOTT XIAOExecutive Officer, Director
- ALEXANDER WENDLANDExecutive Officer, Director
- DEAN A. TRAVERSExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $410K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$250KraisedJul 2016 · 7 investors · OtherRule 506(b)
▶$250KraisedJul 2016 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- DEAN A. TRAVERSExecutive Officer, Director
- SCOTT XIAOExecutive Officer, Director
- ALEXANDER WENDLANDExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $250K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Luminopia went on to found or lead other companies.
Competitors · 3
by search overlap
Seevividly66 shared keywordsVivid Vision builds a vision care platform that uses virtual reality technology to treat conditions such as amblyopia and strabismus. The system is used by eye doctors and distributed worldwide through regional partners.
NovaSight37 shared keywordsNovaSight develops eye-tracking software for detecting and managing myopia, primarily in children and teenagers. Its SaaS product creates real-time myopic blur on screens based on the user's gaze position and monitors visual health by alerting to eye fatigue or dry eye.
Warby Parker29 shared keywordsWarby Parker is a direct-to-consumer eyewear retailer offering prescription eyeglasses, sunglasses, contacts, and eye exams at affordable prices, with a home try-on service and flexible return policy.
Companies competing with Luminopia for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Luminopia do?
- Luminopia is an FDA-cleared binocular therapy for amblyopia in children aged 4-12 that uses a VR headset to stream the child's favorite TV shows as treatment, replacing traditional eye patches. Clinically tested in US trials, the therapy is prescribed by doctors and requires one hour of use per day, six days a week.
- Who founded Luminopia?
- Luminopia was founded by Scott Xiao, Dean Travers in 2015.
- Who are Luminopia's investors?
- Luminopia's investors include ShangBay Capital LLC, Bantam Group, Good Friends, NXT Ventures, Sony Ventures Corporation, US Venture Partners, U.S. Venture Partners.
- How much funding has Luminopia raised?
- Luminopia has disclosed $36.5M raised across 7 rounds.
- Where is Luminopia headquartered?
- Luminopia is headquartered in Aspen, US.